Cytek Biosciences, Inc. (CTKB) net assets (shareholders' equity)
Cytek Biosciences, Inc. (CTKB) had net assets of $341.74M at the end of fiscal 2025 (December 31, 2025). That is 13.6% lower than the $395.74M of fiscal 2024. Figures as of 18 Nov 2026, 18:10 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Net assets, fiscal 2025
- $341.74M
- Change on fiscal 2024
- −13.6%
- Highest on record
- $425.30Mfiscal 2022
- Lowest on record
- -$16.03Mfiscal 2020
- Fiscal years on record
- 62020–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
Cytek Biosciences, Inc. net assets (shareholders' equity), in more detail
Across the 6 fiscal years on record (2020–2025), the highest was $425.30M in fiscal 2022 and the lowest -$16.03M in fiscal 2020.
Net assets by fiscal year
Cytek Biosciences, Inc. net assets (shareholders' equity), year by year
| Fiscal year | Net assets | Change | Year ended |
|---|---|---|---|
| 2025 | $341.74M | 13.6% down | |
| 2024 | $395.74M | 0.7% up | |
| 2023 | $393.06M | 7.6% down | |
| 2022 | $425.30M | 4.9% up | |
| 2021 | $405.39M | — | |
| 2020 | -$16.03M | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value.
How to read it
Large buybacks and write-offs shrink it without the business getting worse, so a falling or negative figure needs the reason before a verdict.
Cytek Biosciences, Inc., figure by figure
- Cytek Biosciences, Inc. market cap
- Cytek Biosciences, Inc. revenue
- Cytek Biosciences, Inc. earnings
- Cytek Biosciences, Inc. earnings per share (EPS)
- Cytek Biosciences, Inc. P/E ratio
- Cytek Biosciences, Inc. P/S ratio
- Cytek Biosciences, Inc. P/B ratio
- Cytek Biosciences, Inc. free cash flow
- Cytek Biosciences, Inc. operating margin
- Cytek Biosciences, Inc. dividend
- Cytek Biosciences, Inc. shares outstanding
- Cytek Biosciences, Inc. total debt
- Cytek Biosciences, Inc. cash on hand
- Cytek Biosciences, Inc. total assets
- Cytek Biosciences, Inc. total liabilities
- Cytek Biosciences, Inc. return on equity (ROE)
- Cytek Biosciences, Inc. return on invested capital (ROIC)
Cytek Biosciences, Inc. (CTKB) overview: price, valuation and scorecard
Cytek Biosciences, Inc. net assets (shareholders' equity): questions and answers
What are Cytek Biosciences, Inc.'s net assets?
Cytek Biosciences, Inc. (CTKB) had net assets of $341.74M at the end of fiscal 2025 (December 31, 2025). That is 13.6% lower than the $395.74M of fiscal 2024.
What are the highest and lowest net assets figures on record for Cytek Biosciences, Inc.?
Across the 6 fiscal years on record (2020–2025), the highest was $425.30M in fiscal 2022 and the lowest -$16.03M in fiscal 2020.
How is Cytek Biosciences, Inc.'s net assets calculated?
Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value. For Cytek Biosciences, Inc. it is on record here for 6 fiscal years, 2020 to 2025.
Fiscal years are named for the calendar year they end in.
Learn: net assets (shareholders' equity)
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Cytek Biosciences, Inc. (CTKB) net assets (shareholders' equity)”, data as of 18 November 2026. https://funkfolio.com/stock/CTKB/net-assets
Underlying data: the company's filings with the SEC and Yahoo Finance.